Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data.
about
Management of Postthrombolysis Hemorrhagic and Orolingual Angioedema ComplicationsPostthrombolysis intracranial hemorrhage risk of cerebral microbleeds in acute stroke patients: a systematic review and meta-analysisThe exact science of stroke thrombolysis and the quiet art of patient selectionTreating the acute stroke patient as an emergency: current practices and future opportunities.Combined Low-Frequency Ultrasound and Urokinase-Containing Microbubbles in Treatment of Femoral Artery Thrombosis in a Rabbit Model.Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III designThrombolytic efficacy of tissue plasminogen activator-loaded echogenic liposomes in a rabbit thrombus model.Covariate imbalance and adjustment for logistic regression analysis of clinical trial data.Magnetic inductive phase shift: a new method to differentiate hemorrhagic stroke from ischemic stroke on rabbitAn Empirical Analysis of the Current Need for Teleneuromedical Care in German Hospitals without Neurology Departments.Therapeutic outcomes of transplantation of amniotic fluid-derived stem cells in experimental ischemic stroke.Systematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended eventIntravenous grafts of amniotic fluid-derived stem cells induce endogenous cell proliferation and attenuate behavioral deficits in ischemic stroke rats.Low frequency mechanical actuation accelerates reperfusion in-vitroTrends in thrombolytic use for ischemic stroke in the United States.Mobilization after thrombolysis (rtPA) within 24 hours of acute stroke: what factors influence inclusion of patients in A Very Early Rehabilitation Trial (AVERT)?Update on the Serum Biomarkers and Genetic Factors Associated with Safety and Efficacy of rt-PA Treatment in Acute Stroke Patients.Failure to report protocol violations in clinical trials: a threat to internal validity?Biomarkers in neurocritical care.Treatment of Rivaroxaban versus Aspirin for Non-disabling Cerebrovascular Events (TRACE): study protocol for a randomized controlled trial.Organizing regional networks to increase acute stroke intervention.Stem Cell-Induced Biobridges as Possible Tools to Aid Neuroreconstruction after CNS Injury.Protocol Deviations before and after Treatment with Intravenous Tissue Plasminogen Activator in Community HospitalsLack of association between pretreatment neurology consultation and subsequent protocol deviation in tissue plasminogen activator-treated patients with stroke.Translating G-CSF as an Adjunct Therapy to Stem Cell Transplantation for Stroke.Spontaneous Splenic Rupture Following Intravenous Thrombolysis with Alteplase Applied as Stroke Therapy - Case Report and Review of Literature.Tissue Plasminogen Activator Prescription and Administration Errors within a Regional Stroke System.Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors.Hemorrhagic transformation: a review of the rate of hemorrhage in the major clinical trials of acute ischemic stroke.The past and future of neuroprotection in cerebral ischaemic stroke.Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.Safety of thrombolysis in acute ischemic stroke: a review of complications, risk factors, and newer technologies.Intravenous thrombolysis with rt-PA in stroke: experience of the moroccan stroke unit.Intravenous thrombolysis with rt-PA in acute stroke patients aged >or=80 years.Systematic reviews as a tool for planning and interpreting trials.A multilevel intervention to increase community hospital use of alteplase for acute stroke (INSTINCT): a cluster-randomised controlled trial.Stem cell-paved biobridges facilitate stem transplant and host brain cell interactions for stroke therapy.Thrombolytic therapy for acute ischaemic stroke: successful implementation in an Australian tertiary hospital.Translational initiatives in thrombolytic therapy.TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours a
P2860
Q26796470-C05D9AEE-72E1-4B64-BD72-999AF842A135Q27001565-19E7BBB3-B00F-4F6C-B1B7-F324185384CEQ27011873-AF4FB5F7-740B-409F-869F-738F94BB5717Q28196628-7EA04DCC-4887-4016-AE2B-8343AA1C5357Q30365436-FD1102E3-6458-4F5E-A1D9-9BB20D9CE56FQ30430118-1E984A6C-85F1-4D1A-BBEB-CE9F063EAEC1Q30448853-481F73CB-8488-4632-A536-6C7DEDAB6990Q30679894-F6816D33-BD80-45DB-B6B8-D63C1D2B4F86Q33743138-2CB9A0A7-6EB6-46D2-8B21-300238DDD250Q34021634-2E311D50-70E6-40BE-875A-61EF788C346DQ34038582-1A25E82F-4F4E-43CD-A63B-9C117BB03C11Q34254787-1844B2F2-664B-4D2D-BD91-069BD4063D7CQ34389750-54F72D60-4EAB-4495-B4DB-D86184D285A6Q34464436-8E6EC7A8-333A-4323-AC02-BC11ECF88B48Q34508464-0BD1AD77-698C-40B7-8993-18AF6FF117BAQ34538611-014FCE91-F3FB-48A9-B1A6-B9CC07758F99Q35109940-D5BDECA0-5895-468E-B604-9DB3B74E86FAQ35338239-4499DFC4-7D5B-46C8-8710-F83C3B63E444Q35729723-77945C58-1A64-46AB-931C-29442F15F512Q35803734-EEA8E643-C247-45C6-BCDA-D2B706035FEDQ36273721-386004E2-3718-45BF-9C5E-1E92C5F1A28DQ36379561-FEAA1B2A-961F-4756-AB27-3239D5C739C3Q36414557-C0A9BCFF-0280-4BBF-85AF-249A321A2B77Q36489502-4F8FB78C-6119-40C9-B8C9-1FB42D62F168Q36522091-8AC1A3CD-D768-465A-8414-226C52A99B0BQ36654730-5DA3FF8A-F343-4726-BCCF-8D053015B46AQ36655960-CD6837E3-5DA8-49FF-8141-428F0B27E79BQ36829303-5D3F6997-48A4-40A3-B021-2EF89FE7D445Q36914630-86B0845A-A2A1-410E-8CD4-8A45E1F31610Q36961362-D31BECB9-36D8-4C35-A3FD-8B21B816D513Q36993122-195F5AA3-1819-4608-A31C-529928A79708Q37052824-EE96BD72-B3BF-4C85-B976-9300E7AC7FB4Q37354624-70705B30-0C18-4524-9C7B-AC274EB718DBQ37399437-D4980D07-8403-4753-986D-4B3DABEC609BQ37399439-27CB6CB7-77F3-4FC5-8938-26FA7E30448CQ37612420-A0B77968-C2CA-4EDF-AB78-BDC256A50164Q38377637-52EEC77A-5EAC-4922-9546-866C532396F1Q38452178-BDAF0BFA-D9CB-46A5-AE83-1819550EEDDFQ39100187-1392B90F-9769-4967-AFBD-27E456C04020Q42634449-F9B5D0AA-D839-40E2-9281-A91FC4D5C0DB
P2860
Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Tissue plasminogen activator f ...... meta-analysis of safety data.
@ast
Tissue plasminogen activator f ...... meta-analysis of safety data.
@en
type
label
Tissue plasminogen activator f ...... meta-analysis of safety data.
@ast
Tissue plasminogen activator f ...... meta-analysis of safety data.
@en
prefLabel
Tissue plasminogen activator f ...... meta-analysis of safety data.
@ast
Tissue plasminogen activator f ...... meta-analysis of safety data.
@en
P1433
P1476
Tissue plasminogen activator f ...... meta-analysis of safety data.
@en
P2093
Glenn D Graham
P304
P356
10.1161/01.STR.0000101752.23813.C3
P407
P577
2003-11-06T00:00:00Z